Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pitts

Showing results (221-230 of 268) with videos related to

Pageof 27
Sort By:
Frontiers in Oncology|April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal AdenocarcinomaSarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Oncotarget|October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenograftsChristopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
Investigational New Drugs|October 27, 2016
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)Kit Man Wong, Lindsey N Micel, Heather M Selby, et al.
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Translational Psychiatry|March 20, 2014
Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS studyS Maltezos, J Horder, S Coghlan, et al.
Molecular Cancer Therapeutics|October 7, 2010
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancerJohn J Tentler, Sujatha Nallapareddy, Aik Choon Tan, et al.
Molecular Cancer Therapeutics|June 6, 2020
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal CancerJoshua M Abbott, Qiong Zhou, Hector Esquer, et al.
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
Molecular Cancer Therapeutics|November 8, 2014
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explantsLindsey N Micel, John J Tentler, Aik-Choon Tan, et al.
Plos One|November 18, 2014
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerTodd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, et al.
Pageof 27

Showing results (221-230 of 268) with videos related to

Sort By:
Pageof 27
Frontiers in Oncology|April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal AdenocarcinomaSarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Oncotarget|October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenograftsChristopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
Investigational New Drugs|October 27, 2016
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)Kit Man Wong, Lindsey N Micel, Heather M Selby, et al.
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Translational Psychiatry|March 20, 2014
Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS studyS Maltezos, J Horder, S Coghlan, et al.
Molecular Cancer Therapeutics|October 7, 2010
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancerJohn J Tentler, Sujatha Nallapareddy, Aik Choon Tan, et al.
Molecular Cancer Therapeutics|June 6, 2020
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal CancerJoshua M Abbott, Qiong Zhou, Hector Esquer, et al.
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
Molecular Cancer Therapeutics|November 8, 2014
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explantsLindsey N Micel, John J Tentler, Aik-Choon Tan, et al.
Plos One|November 18, 2014
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerTodd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, et al.
Pageof 27